Wegovy is the first GLP-1 medication for weight loss to gain approval from the FDA. The organization approved it in 2021. However, there are strict eligibility criteria that you will need to meet ...

Group revenues came in at DKK 65.3 billion ($9.3 billion) – ahead of analyst expectations – with GLP-1 agonist Wegovy (semaglutide) contributing DKK 9.4 billion of the total. Novo Nordisk said ...